Consensus Foghorn Therapeutics Inc.

Equities

FHTX

US3441741077

Market Closed - Nasdaq Other stock markets 21:30:00 03/05/2024 BST			5-day change	1st Jan Change
5.99 ^USD	-1.96%		+9.11%	-7.13%

04-16	Foghorn Therapeutics Names Kristian Humer CFO	MT
04-16	Foghorn Therapeutics Inc. Appoints Kristian Humer as Chief Financial Officer	CI

Evolution of the average Target Price on Foghorn Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

7ffe5241c7b88e37ae5b40.tXtLrqIf3Rp1aJZLcnsfygbviGCGP_SvrZ_cqieXeoM.zDEv_ZptpVUzGd9mN0lHmFaOzjL0e8T8mOa0_XDVA_XTQzzi8E2TVB5Rpg~3d5ab3c9d47f0cccee17bc57b3824892

Analyst Recommendations on Foghorn Therapeutics Inc.

Morgan Stanley Adjusts Price Target on Foghorn Therapeutics to $6 From $10, Maintains Equalweight Rating	11-13	MT
Morgan Stanley Adjusts Price Target on Foghorn Therapeutics to $10 From $13, Maintains Equal-Weight Rating	06/07/23	MT
Goldman Sachs Cuts Foghorn Therapeutics' Price Target to $19 From $21, Keeps Buy Rating	29/06/23	MT
Wedbush Trims Foghorn Therapeutics Price Target to $13 From $14, Maintains Outperform Rating	28/06/23	MT
HC Wainwright Adjusts Price Target on Foghorn Therapeutics to $20 From $25, Keeps Buy Rating	09/05/23	MT
Wedbush Trims Foghorn Therapeutics' Price Target to $14 From $15, Tweaks Financing Assumptions; Keeps Outperform Rating	09/05/23	MT
BMO Capital Adjusts Price Target on Foghorn Therapeutics to $19 From $20, Maintains Outperform Rating	25/04/23	MT
Wedbush Lowers Foghorn Therapeutics' Price Target to $15 From $20 After Pause in Enrollment for FHD-609 Program, Keeps Outperform Rating	25/04/23	MT
BofA Securities Initiates Coverage on Foghorn Therapeutics With Buy Rating, $10 Price Target	28/03/23	MT
Wedbush Lowers Foghorn Therapeutics's Price Target to $20 From $25, Tweaks Timing Around Programs; Keeps Outperform Rating	10/03/23	MT
BMO Capital Starts Foghorn Therapeutics at Outperform With $20 Price Target	05/01/23	MT
Morgan Stanley Adjusts Foghorn Therapeutics Price Target to $14 From $15, Maintains Equal Weight Rating	21/11/22	MT
Morgan Stanley Downgrades Foghorn Therapeutics to Equalweight From Overweight, Lowers Price Target to $15 From $25	24/08/22	MT
ANALYST RECOMMENDATIONS : Intuit, XPeng, Rio Tinto, Prologis, Charter Communications...	24/08/22
Morgan Stanley Downgrades Foghorn Therapeutics to Equalweight From Overweight, Cuts Price Target to $15 From $25	23/08/22	MT
Wedbush Cuts Price Target on Foghorn Therapeutics to $25 From $32, Citing FHD-286 Clinical Hold; Outperform Rating Kept	23/08/22	MT
Wall Street Stabilizes Pre-Bell After Slump Fueled by Rate Hike Concerns	23/08/22	MT
HC Wainwright Increases Foghorn Therapeutics' Price Target to $25 From $18, Maintains Buy Rating	10/08/22	MT
Goldman Sachs Adjusts Foghorn Therapeutics' Price Target to $21 from $30, Keeps Buy Rating	24/05/22	MT
Morgan Stanley Adjusts Price Target for Foghorn Therapeutics to $25 From $26, Maintains Overweight Rating	23/05/22	MT
Wall Street Set for Gains as China Rate Cut Boosts Sentiment	20/05/22	MT
HC Wainwright Adjusts Foghorn Therapeutics' Price Target to $18 From $25, Keeps Buy Rating	20/05/22	MT
Wedbush Adds Outperform-Rated Foghorn Therapeutics to Best Ideas List; Price Target is $32	11/03/22	MT
Morgan Stanley Raises Price Target for Foghorn Therapeutics to $26 From $23, Maintains Overweight Rating	15/12/21	MT
Wedbush Raises Price Target for Foghorn Therapeutics to $32 From $24 on Eli Lilly Collaboration, Maintains Outperform Rating	13/12/21	MT